Upcoming Events at the San Diego Chapter

Chapter Homepage

Tuesday, September 19, 2006
6:00-8:00 p.m.

The San Diego Chapter of the Licensing Executives Society
Panel Discussion Featuring:

"Intellectual Property, Licensing, Spin-outs & Related Business Affairs of Non-Profit Organizations"

Sponsored by:

SPEAKERS:
CRAIG DIONNE, Ph.D. – PRESIDENT AND CEO,GENSPERA, INC. (Formerly Executive Vice President, Research and Therapeutics at the Prostate Cancer Foundation)
A. STEPHEN DAHMS, Ph.D. – PRESIDENT& CEO, ALFRED E. MANN FOUNDATION FOR BIOMEDICAL ENGINEERING
JANE MOORES, Ph.D.  – ASSISTANT DIRECTOR, LIFE SCIENCE LICENSING, TECHNOLOGY TRANSFER AND INTELLECTUAL PROPERTY SERVICES (TechTIPS), University of California, San Diego
Moderator:
VASU PESTONJAMASP, Ph.D. –  MANAGING DIRECTOR, BIO-I.P. MANAGEMENT CO.

PROGRAM DESCRIPTION:
Warren Buffet's $31 billion-dollar charitable bequest of Berkshire Hathaway stock to the Bill & Melinda Gates Foundation in June dramatically underscored for the world the importance and growing magnitude of non-governmental, non-profit organizations in global healthcare R&D and humanitarian aid.  California and San Diego are likewise well-endowed with many well-funded non-profits either directly engaged in healthcare-related R&D such as Scripps, the Salk Institute and the Burnham Institute, or merely acting as funding sources, such as The California Institute for Regenerative Medicine (CIRM) and The Preuss Foundation.

Intellectual property (I.P.) rights in the non-profit context run the gamut from being the sole property of individual inventors, to Bayh-Dole regimes a la NIH- and CIRM-derived funding, to Woodstock-like communal "un-I.P." in the case of the Gates Foundation's $287 million program for HIV/AIDS vaccine research announced in July.  So should the typical non-profit organization attempt to "profit" from the I.P. its funding or activities create?  And if yes, how should this be done while maintaining a non-profit status?

This animated panel of industry glitterati will discuss the strategic, legal, licensing and ethical issues straddling the demarcation line between the non-profit and for-profit worlds.  After a long summer idyll, get recharged and reconnected with your LES colleagues at this kick-off meeting of our Fall programming schedule.

DATE:
Tuesday, September 19, 2006

TIME:
6:00 p.m. – 6:50 Registration, Networking, Cocktails and Appetizers
6:50 p.m. – 7:00 p.m. Chapter Business
7:00 p.m. – 8:00 p.m. Panel Discussion

LOCATION: 
Hyatt Regency La Jolla, 3777 La Jolla Village Drive
(PLEASE NOTE, THIS IS A CHANGE OF LOCATION.)

COST:
Pre-Register by 12 noon on Friday, September 15, 2006 

$35 Members by Friday September 15, $45 at the door (cash or check only)
$40 Non-Members by Friday September 15,  $50 at the door (cash or check only)

$20 Member Student Rate, and $25 Non-Member Student Rate paid at the door
(cash or check only) until the website is setup for on line registration

REGISTRATION OPTIONS:
You have the option of registering online and paying either by credit card OR check

Pre-registration not only guarantees you a seat, but it also saves you $10. 

LES Members, click here to register online with your credit card;

Non-Members, click here to register with your credit card;

Seating is limited and will be on a first come, first served basis.  Please note that we will still need to receive your check by Friday, September 15, to guarantee your registration. The address to mail your check to is:

Chris Steinhardt 
c/o Knobbe Martens Olson & Bear LLP
550 West C Street, Suite 1200
San Diego, CA 92101
619-235-8550  619-235-0176 Fax
e-mail: csteinhardt@kmob.com

For additional information, please contact:

NOTE:   This presentation will qualify for MCLE credit

PANELISTS’ BIOGRAPHIES

Craig A. Dionne, Ph.D., President and Chief Executive Officer, GenSpera, Inc.
Dr. Dionne has over 18 years experience in the pharmaceutical industry with increasing levels of responsibility throughout his career. He is currently the President and CEO of GenSpera, Inc., a start-up biotechnology company developing novel drugs for prostate cancer. He recently served as Executive Vice President, Research and Therapeutics at the Prostate Cancer Foundation (PCF), a not-for-profit foundation whose mission is to find better treatments for advanced prostate cancer. Prior to PCF he served five years as a Vice-President in Discovery Research at Cephalon, Inc., where he was responsible for drug discovery programs in the areas of Oncology and Neurobiology. His efforts at Cephalon were instrumental in identifying four different drugs that were brought into clinical evaluation over a span of six years. He has extensive experience in corporate collaborations, having served on Joint Management Teams in various capacities with eight different corporate partners while with Cephalon, Inc. He received his doctorate from the University of Texas in 1984, was trained as a postdoctoral fellow at Dana-Farber Cancer Institute and worked as a Research Fellow at Rhone-Poulenc Rorer before joining Cephalon, Inc. in 1992. Dr. Dionne has had an extensive and productive scientific career as evidenced by co-inventorship on 6 issued United States patents and co-authorship of over 50 scientific publications.

A. Stephen Dahms, Ph.D., President and CEO, Alfred. E. Mann Foundation for Biomedical Engineering
Dr. Dahms is President and CEO of the Alfred. E. Mann Foundation for Biomedical Engineering and oversees the creation of 12-15 new biomedical product commercialization institutes at elite U.S. universities with initial funding at $150-200 m each.  Prior to that, as a biochemist - molecular biologist, he was Professor of Chemistry at San Diego State University (1972-2006), founding director of the SDSU Molecular Biology Institute (1974-1992), director of the SDSU Biotechnology Research Program (1992-96), Director of the SDSU Center for Bio/Pharmaceutical and Biodevice Development (1996-2006) and Executive Director of CSUPERB, the biotechnology research and education program in the 23-campus California State University (CSU) system, the nation's largest university system from 1987-2006. He serves on the boards of directors for a number of biotechnology trade groups and organizations and research foundations, including the Biotechnology Industry Organization (BIO) Emerging Company Section, BayBIO, BIOCOM San Diego, and other regional organizations representing over 50% of the U.S. biotechnology and medical device industries. He is Chair of the Board of Directors of the U.S. Council of Biotechnology Centers/BIO and addresses complex issues in the technology transfer, translational research, and pre-commercialization phases of the biomedical innovation cycle. He is a member of the National Research Council National Materials Advisory Board’s and Institute of Medicine’s Roundtable on Biomedical Engineering Materials and Applications and serves on a number of national and international committees and commissions addressing the academic-bio/pharm/med device industry interfaces and the facilitation of interdisciplinary and translational research.

JANE MOORES, Ph.D., Assistant Director, Life Science Licensing, Technology Transfer and Intellectual Property Services (TechTIPS), University of California, San Diego
Dr. Moores is currently Assistant Director, Life Science Licensing in the Technology Transfer and Intellectual Property Services (TechTIPS) office at the University of California, San Diego.  TechTIPS manages the intellectual property of UCSD and Dr. Moores focuses on licensing inventions in the biomedical and life science sector.  She is also involved in establishing relationships with local, national and international business and academic communities.

Before joining TechTIPS in 1999, Dr. Moores spent 12 years at Stratagene, a San Diego company that supplies biological reagents and instruments to the research community.  During her time at Stratagene, Dr. Moores worked in product research and development, and also in several aspects of business development.

Dr. Moores holds B.Sc. and  Ph.D. degrees in microbiology from University College, London.  She performed post-doctoral research at UCSD in the Chemistry Department, where she was involved in cloning bacterial genes, and in the School of Medicine, where she helped to develop retroviral vectors for gene therapy under the mentorship of Dr. Theodore Friedmann. 

Vasu Pestonjamasp, Ph.D.,  Principal, Bio-I.P. Management Co.
Dr. Pestonjamasp is the Principal of Bio-I.P. Management Co., a San Diego-based consulting firm specializing in scientific and technical writing, technology evaluation, and advising about business development/marketing strategies.
 
Dr. Pestonjamasp has been a member of societies/associations in the biotech and philanthropic fundraising areas.   She has extensive public speaking experience, and has been the originator, organizer, and Chair/Co-chair of such first-in-class conferences as Strategic Research Institute’s (SRI’s) Pharma & Biotech Intellectual Property & Patents Summit, as well as annual business workshops and technical sessions held during BIO-Europe and IBC’s BioAsia conferences.  Dr. Pestonjamasp has also been on the planning committees for major special events in the philanthropy area.
 
Dr. Pestonjamasp has received numerous awards for academic excellence, obtained grant funding and has a distinguished record of research published in various peer-reviewed scientific journals.  She completed her postdoctoral research at Harvard Medical School and the University of California San Diego (UCSD), and also did project work at the University of Massachusetts Medical Center in Worcester, Massachusetts.  She received her Ph.D. from Cancer Research Institute, University of Bombay, India.

Knobbe, Martens, Olson & Bear, LLP
With over 175 lawyers, Knobbe Martens Olson & Bear LLP represents clients in all areas of intellectual property law and litigation. Clients include public and private companies at various stages of growth, from start-up to the Fortune 500 worldwide. Founded in 1962, the firm is one of the largest intellectual property law firms in the United States. The firm has been recognized in international surveys for excellence in all aspects of intellectual property law. In addition, several members of the firm have been voted among the world's leading intellectual property lawyers. More information about the firm can be found on its website: www.kmob.com.